Ann: CRA Health Acquisition Presentation, page-44

I am a bit harsh suggesting VHT should be at US$390M. However 27% of that figure is what investors expected after acquiring MRS (US$105M).

US$13.5M vs $US105M.
We failed due to one measure, ARPU. The US$10 figure never transpired and we saw US$1.22 after significant churn and lack of cross-selling opportunities. Such a misrepresentation. How can we expect any different with CRA? More likely that ARPU will drop to $1, than $10 ever being achieved.

It is so simple to praise management, but they are taking you for a bumpy ride. This ride is a constant dilution journey.